Keene & Associates Inc. Buys 1,360 Shares of Smith & Nephew plc (NYSE:SNN)

Keene & Associates Inc. grew its stake in shares of Smith & Nephew plc (NYSE:SNN) by 13.2% during the second quarter, Holdings Channel.com reports. The institutional investor owned 11,700 shares of the medical equipment provider’s stock after acquiring an additional 1,360 shares during the quarter. Keene & Associates Inc.’s holdings in Smith & Nephew were worth $290,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brandes Investment Partners LP bought a new stake in Smith & Nephew in the fourth quarter valued at approximately $29,884,000. Optiver Holding B.V. increased its position in shares of Smith & Nephew by 100.4% in the 4th quarter. Optiver Holding B.V. now owns 599,981 shares of the medical equipment provider’s stock valued at $16,476,000 after buying an additional 300,591 shares in the last quarter. Hsbc Holdings PLC raised its stake in Smith & Nephew by 80.1% during the 4th quarter. Hsbc Holdings PLC now owns 592,734 shares of the medical equipment provider’s stock worth $16,152,000 after buying an additional 263,641 shares during the period. Wells Fargo & Company MN lifted its holdings in Smith & Nephew by 20.9% during the fourth quarter. Wells Fargo & Company MN now owns 1,003,050 shares of the medical equipment provider’s stock worth $27,363,000 after acquiring an additional 173,448 shares in the last quarter. Finally, Tocqueville Asset Management L.P. grew its stake in Smith & Nephew by 294.9% in the first quarter. Tocqueville Asset Management L.P. now owns 224,441 shares of the medical equipment provider’s stock valued at $5,692,000 after acquiring an additional 167,599 shares during the period. 25.64% of the stock is owned by institutional investors.

Smith & Nephew Trading Up 0.5 %

NYSE SNN opened at $31.50 on Monday. Smith & Nephew plc has a 52 week low of $21.52 and a 52 week high of $31.72. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The stock’s 50 day moving average price is $29.79 and its two-hundred day moving average price is $26.94.

Smith & Nephew Increases Dividend

The firm also recently announced a dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 4th will be issued a dividend of $0.288 per share. This is a boost from Smith & Nephew’s previous dividend of $0.24. The ex-dividend date is Friday, October 4th.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on SNN shares. Deutsche Bank Aktiengesellschaft initiated coverage on Smith & Nephew in a research report on Wednesday, July 24th. They set a “buy” rating on the stock. StockNews.com raised shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Monday, August 5th. Finally, UBS Group upgraded Smith & Nephew from a “neutral” rating to a “buy” rating in a report on Wednesday, June 5th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.